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Abstract
Background: Steatosis is occasionally reported during screening ultrasonography in patients with
hepatitis C virus (HCV). We conducted a retrospective observational study to assess the factors
associated with steatosis on ultrasonography and the relationship between steatosis on ultrasound
versus biopsy in patients infected with HCV in a clinical setting. Our hypothesis was
ultrasonography would perform poorly for the detection of steatosis outside of the context of a
controlled study, primarily due to false-positive results caused by hepatic fibrosis and inflammation.
Methods: A retrospective review of ultrasound reports was conducted on patients infected with
HCV in a tertiary care gastroenterology clinic. Reports were reviewed for the specific
documentation of the presence of steatosis. Baseline clinical and histologic parameters were
recorded, and compared for patients with vs. without steatosis. Multiple logistic regression analysis
was performed on these baseline variables. Liver biopsies were reviewed by two pathologists, and
graded for steatosis. Steatosis on biopsy was compared to steatosis on ultrasound report, and the
performance characteristics of ultrasonography were calculated, using biopsy as the gold standard.
Results: Ultrasound reports were available on 164 patients. Patients with steatosis on ultrasound
had a higher incidence of the following parameters compared to patients without steatosis: diabetes
(12/49 [24%] vs. 7/115 [6%], p < 0.001), fibrosis stage >2 (15/48 [31%] vs. 16/110 [15%], p = 0.02),
histologic grade >2 (19/48 [40%] vs. 17/103 [17%], p = 0.002), and ALT (129.5 ± 89.0 IU/L vs. 94.3
± 87.0 IU/L, p = 0.01). Histologic grade was the only factor independently associated with steatosis
with multivariate analysis. When compared to the histologic diagnosis of steatosis (n = 122),
ultrasonography had a substantial number of false-positive and false-negative results. In patients
with a normal ultrasound, 8/82 (10%) had >30% steatosis on biopsy. Among patients with steatosis
reported on ultrasound, only 12/40 (30%) had >30% steatosis on biopsy review.
Conclusion: Steatosis on ultrasound is associated with markers of inflammation and fibrosis in
HCV-infected patients, but does not consistently correlate with steatosis on biopsy outside of the
context of a controlled study. Clinicians should be skeptical of the definitive diagnosis of steatosis
on hepatic ultrasonography.
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Background
Hepatic steatosis is commonly detected on both radio-
logic and histologic examination in patients infected with
the hepatitis C virus (HCV). In particular, steatosis is often
observed in genotype 3 infection [1]. The underlying
mechanism of steatosis in hepatitis C is not completely
understood, and is most likely multifactorial. Animal
models [2,3] and in vitro experimentation [4] suggest that
a virologic effect induces steatosis. Clinical observational
data suggest that a possible direct virologic effect occurs
with hepatitis C genotype 3 infection [1,5]. However, stea-
tosis in genotype 1 and 2 HCV infections is more closely
related to risk factors that are known to be associated with
non-alcoholic steatohepatitis (i.e. diabetes mellitus and
obesity)[5,6]. The assessment of steatosis may have clini-
cal relevance, as some studies have suggested that the
detection of steatosis can be an independent predictor of
response to therapy [7].
Clinicians routinely order hepatic ultrasonography on
patients with hepatitis C as an initial screening test for
hepatocellular carcinoma or anatomic abnormality. In
ordering this test, the radiologist may also detect and
mention steatosis. However, the diagnosis of steatosis on
ultrasound can be problematic, as the ultrasonic appear-
ance of steatosis may be that of a 'bright liver,' which can
also be observed with hepatic fibrosis and/or inflamma-
tion [8]. Even though these overlap syndromes exist, we
observed a number of hepatic ultrasonography reports
identifying steatosis in our clinical practice, as opposed to
echogenic or 'bright liver'.
The sensitivity and specificity of ultrasonography for the
detection of steatosis may be very high in the hands of an
expert radiologist who consistently applies a particular cri-
teria. However, many clinicians in the United States
employ the services of a radiology department or group,
in which many radiologists with varying levels of experi-
ence actually interpret the images. We were interested in
the utility of a report of steatosis in this context.
Only one prior study has compared steatosis on ultra-
sound to histology in HCV-infected patients [9], and no
correlation was observed between histologic and radio-
logic results. However, the conclusions of this study are
limited since the diagnosis of HCV was based on the
detection of HCV antibodies, rather than a determination
of viremia with polymerase chain reaction (PCR) technol-
ogy. Additionally, this study was not performed in the
context of clinical practice.
We conducted a retrospective observational study to
assess the radiology reports of hepatic ultrasonography of
HCV-infected patients. Our purpose was to determine
demographic, clinical and laboratory characteristics asso-
ciated with radiology reports of steatosis on ultrasound in
HCV-infected patients and to describe the association
between steatosis on ultrasound and steatosis on liver
biopsy. We specifically wanted to clarify the implications
of the identification of steatosis on an ultrasound report
for the practicing clinician. Our purpose was not to assess
the performance characteristics of hepatic ultrasonogra-
phy under controlled conditions. Rather, we were inter-
ested in the utility of these reports in routine clinical
practice, with different radiologists over a three-year
period. The first part of our analysis was to examine all
patients who had hepatic ultrasonography performed,
including patients who did not have a liver biopsy. The
second part of our analysis (comparing steatosis on ultra-
sound report to steatosis on biopsy) included only
patients who had hepatic ultrasonography and liver
biopsy. We observed that ultrasound reports of hepatic
steatosis were particularly associated with histologic
inflammation, as well as fibrosis, and the sensitivity and
specificity of steatosis on ultrasound was poor, when
compared to steatosis on biopsy.
Methods
Patients
A retrospective review was performed of all patients who
underwent screening hepatic ultrasonography seen in the
hepatitis research clinic at our tertiary care, military aca-
demic medical center over a three-year period. Patients
were those eligible for care at a military treatment facility,
including active duty military personnel, their spouses,
and military retirees (serving 20 or more years on active
duty). All patients had hepatitis C infection, confirmed by
serum HCV RNA PCR testing. Patients were referred from
primary care clinics at our institution, and military pri-
mary care clinics throughout the region (Texas, Louisiana,
Oklahoma, Kansas, Missouri and Colorado) for further
assessment of their hepatitis C infection and for discus-
sion of treatment options. The Institutional Review Board
at Brooke Army Medical Center approved the study.
Demographic and Clinical Characteristics: Age, gender,
body mass index (BMI) and ethnicity were recorded on
each patient and utilized for analysis. The following labo-
ratory parameters were noted: alanine aminotransferase
(ALT), alpha-fetoprotein (AFP), and HCV genotype.
Patients were considered to have diabetes if they were tak-
ing medication for diabetes treatment. Liver biopsy
reports included a Metavir stage (0=no fibrosis to 4=cir-
rhosis) [10] and histologic grade (0–4, with 0=no inflam-
mation to 4=severe inflammation), which were also
included in the analysis. Each of these parameters was
converted into a binomial variable, with 0–2 and 3–4 as
the resultant two categories.BMC Gastroenterology 2005, 5:14 http://www.biomedcentral.com/1471-230X/5/14
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Ultrasonography
All patients underwent hepatic ultrasonography during
their initial evaluation if they did not have an ultrasound
report from a prior assessment. Computerized records
were reviewed for the ultrasonography reports. Ultra-
sonography was primarily performed at Brooke Army
Medical Center, the same institution as our hepatitis
research clinic. The machines utilized in the Radiology
Department were the ATL Ultramark HDI 3000® Ultra-
sound System and the ATL Ultramark HDI 5000® Ultra-
sound System. A small number of patients in the hepatitis
research clinic (<10%) are referred from Wilford Hall Air
Force Medical Center, also located in San Antonio, Texas.
If the patient had their ultrasound performed at the Air
Force hospital, they were included in the analysis. The
Radiology Departments at these two institutions (Brooke
Army Medical Center and Wilford Hall Air Force Medical
Center) maintain a combined accredited teaching pro-
gram for radiology residents. These reports were scored as
a binomial variable. If the ultrasound report mentioned
steatosis as a finding, it was designated positive. If the
ultrasound report did not mention steatosis, it was
labeled negative. Equivocal studies containing phrases
such as "possible steatosis" or "inflammation or steatosis"
were excluded from the final analysis. Reports did not dis-
tinguish between diffuse or focal fatty liver.
Histologic Examination
A liver biopsy was offered to patients during their initial
evaluation in order to assess the patient's severity of dis-
ease. Liver biopsies were generally performed within 1–2
months of hepatic ultrasound. There were no liver biop-
sies in this study utilized that were > 6 months after ultra-
sonography. The initial histologic examination of the
biopsy focused on the histologic stage (fibrosis) and grade
(inflammation). For our study, two pathologists (J.A.V.
and E.P.F.) retrospectively reviewed these biopsies and a
percentage of steatosis was assigned to each biopsy speci-
men. Any steatosis was denoted as 1%, while a complete
absence of steatosis was classified as 0%. If steatosis was
considered >2%, it was recorded in 5% increments. These
pathologists were blinded to ultrasound results, as well as
any clinical characteristics of the patients. In order to
explore the relationship between the report of steatosis on
ultrasound compared to biopsy, the biopsies were catego-
rized three different ways:
1) grouped into 5 categories (based on the percentage of
steatosis on biopsy): 0–2%, 2–10%, 10–30%, 30–60%,
and >60%.
2) As a binomial, comparing no steatosis (<2%) vs. any
steatosis (>2%).
3) As a binomial, comparing significant steatosis (>30%)
vs. not significant steatosis (<30%).
Analysis
Descriptions of the 'operative characteristics' (sensitivity,
specificity, positive predictive value, negative predictive
value) of steatosis on ultrasound in our clinical setting
were calculated, with the assumption that the gold stand-
ard for the diagnosis of hepatic steatosis was histologic
examination. These calculations were performed for both
the determination of any steatosis and significant steatosis
on histologic examination. Any steatosis was defined as
more than 2% steatosis on biopsy, while significant stea-
tosis was defined as >30% steatosis on biopsy. Prior liter-
ature suggests that ultrasonography performs well in the
diagnosis of significant steatosis [11].
Demographic, clinical and histologic characteristics were
compared between patients with steatosis on biopsy ver-
sus patients without steatosis on biopsy. For continuous
variables, an independent sample t-test was utilized if
their distribution was normal. For continuous variables in
which the distribution of values was not normal, the
Mann-Whitney rank sum test was used. For categorical
variables, a Pearson's chi-square test was employed. To
determine the association between steatosis on ultra-
sound and steatosis on biopsy, a Spearman's rank correla-
tion coefficient was calculated. A kappa-statistic was
calculated to assess interobserver variability between stea-
tosis percentages observed by the two pathologists. Agree-
ment between pathologists was determined to be +/- 5%
for the liver biopsies examined.
A multiple logistic regression model, with stepwise back-
ward elimination of non-significant variables, was devel-
oped to determine factors that were associated with the
detection of steatosis on ultrasound. Steatosis on ultra-
sound was the dependent variable, with the independent
variables including: age, gender, histologic stage (as a
binomial variable), histologic grade (as a binomial varia-
ble), ALT, genotype (genotype 3 compared to all other
genotypes), body mass index, and a history of diabetes.
All variables were included in the model.
Results
Pre-treatment hepatic ultrasound reports were available
on 171 patients. Seven reports were excluded because of
equivocal descriptions (see Methods section, reports of
"inflammation or fatty infiltration," or "steatosis vs. fibro-
sis" were excluded). A total of 49/164 (30%) of patients
had steatosis documented in the ultrasound report. The
comparison of baseline and clinical characteristics
between patients with versus without steatosis on ultra-
sound indicated significant differences in ALT and AFP, aBMC Gastroenterology 2005, 5:14 http://www.biomedcentral.com/1471-230X/5/14
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history of diabetes mellitus, and advanced histologic stage
and grade (Table 1).
Liver biopsy specimens were available from 122 patients
for our pathologists to assess the amount of steatosis. The
remaining 42 patients either did not have an initial liver
biopsy (n = 6) or their liver biopsy slides were not availa-
ble at our institution (n = 36), as they had been returned
to the patient's referring institution. The kappa statistic for
interobserver reliability of steatosis between the two
pathologists was calculated to be 0.87. A relationship
between steatosis on ultrasound and steatosis on biopsy
was detected (Figure 1). The Spearman's rank correlation
coefficient was rs = 0.27 (p = 0.003, n = 122). Of the 122
patients that had both histologic review and ultrasound,
40 (33%) had steatosis noted on their ultrasound report.
A substantial number of false-positive and false-negative
results were observed. For example, 10% (8/82) of
patients with a normal ultrasound had >30% steatosis on
biopsy. Among patients with steatosis reported on ultra-
sound, only 12/40 (30%) had >30% steatosis on biopsy
review.
We determined the test characteristics for steatosis on
ultrasound (in the clinical setting of our study) compared
to biopsy as the gold standard, which were calculated for
the detection of any steatosis (>2%), or for significant
steatosis (>30%) (Table 2). For either of these calcula-
tions, the sensitivity and specificity of ultrasonography
were not high. We also examined whether or not the diag-
nosis of steatosis on ultrasound was more useful in detect-
ing substantial fibrosis (Metavir stage 3–4) on biopsy. The
sensitivity of steatosis on ultrasound predicting fibrosis
on biopsy was 48%, while the specificity was 74%. These
performance characteristics for assessing fibrosis were very
similar to the effectiveness of ultrasonography to correctly
identify significant (>30%) steatosis on biopsy.
A total of 136 patients were included in the multivariate
logistic regression model to determine factors associated
with steatosis on ultrasound (see Methods for variables
included in the model). The other 28 patients were not
included due to a missing variable (genotype not per-
formed, liver biopsy not performed, etc). The only statis-
tically significant factor associated with steatosis on
ultrasound was histologic grade (OR 3.6, 95% CI 1.3–
9.8). A history of diabetes mellitus approached statistical
significance (OR 3.8, 95% CI 0.96–14.70). No other fac-
tors were independently associated with steatosis on
ultrasound.
Discussion
The detection of steatosis on ultrasound in a clinical set-
ting appears to be generally associated with steatosis on
biopsy, but also with hepatic inflammation and fibrosis.
In particular, steatosis on ultrasound was independently
associated with moderate-severe histologic inflammation.
The ability of ultrasonography to accurately detect hepatic
steatosis is questionable outside of a controlled research
setting, as both the sensitivity and specificity of this imag-
ing technique were unacceptably low in our study. An
ultrasound report of steatosis was as predictive of fibrosis
as it was predictive of >30% steatosis, which reflects the
unreliability of this imaging modality in differentiating
fibrosis and steatosis. Based on the results of our study,
the clinician should understand that an ultrasound report
of steatosis could mean the patient has fibrosis, inflam-
mation, significant steatosis, or a combination of these
conditions. Alternatively, the patient may have none of
these pathologic findings. Practitioners should rely on
other diagnostic modalities to assess the liver for steatosis.
Magnetic resonance imaging or computerized tomogra-
phy are two potential techniques that may be clinically
useful in the diagnosis of hepatic steatosis, pending fur-
ther study [12].
Table 1: Comparison of demographic, clinical and laboratory characteristics of patients with versus without steatosis on hepatic 
ultrasound. Legend: ALT- alanine aminotransferase; AFP- alpha fetoprotein; BMI- body mass index.
Parameter Steatosis No Steatosis p value
Gender (% male) 31/49 (63%) 77/115 (67%) 0.68
Genotype (3 vs. others) 4/46 (9%) 5/110 (5%) 0.31
Diabetes (% with DM) 12/49 (24%) 7/115 (6%) 0.001
Age 47.9 ± 10.3 46.3 ± 10.3 0.38
ALT (IU/L) 129.5 ± 89.0 94.3 ± 87.0 0.01
AFP (ng/ml) 13.1 ± 25.5 8.0 ± 12.3 0.03
BMI (kg/m2) 28.6 ± 5.1 27.4 ± 4.8 0.17
Stage (% stage 3–4) 15/48 (31%) 16/110 (15%) 0.02
Grade (% stage 3–4)* 19/48 (40%) 17/103 (17%) 0.002
*Seven histology reports scored only stage, and did not report a histologic grade.BMC Gastroenterology 2005, 5:14 http://www.biomedcentral.com/1471-230X/5/14
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Hepatic steatosis, detected by histologic examination,
appears to have a multifactorial etiology in patients
infected with hepatitis C. Steatosis may be a result of a
direct virologic effect, particularly in patients infected with
genotype 3 [1,5]. Additionally, steatosis in HCV-infected
patients may be associated with accepted steatosis risk fac-
tors, including obesity [6,13,14], diabetes mellitus [6] and
hypertriglyceridemia [13]. We observed that steatosis on
ultrasonography was associated with factors representa-
tive of inflammation (histologic grade on biopsy and
ALT) and fibrosis (histologic stage on biopsy and alpha-
fetoprotein levels [15]) as well as diabetes mellitus. We
did not observe an obvious association between genotype
or body mass index with steatosis on ultrasound. Lack of
Comparison of steatosis on biopsy versus ultrasound Figure 1
Comparison of steatosis on biopsy versus ultrasound. For each of the five categories of amount of steatosis on biopsy, 
the percentage of patients in those categories with a positive ultrasound for steatosis is displayed. rs = 0.27, p = 0.003.
Table 2: Performance characteristics of the detection of steatosis on ultrasound (n = 122). PPV = positive predictive value; 
NPV=negative predictive value. Gold standard was steatosis on histologic examination.
Histologic Examination Sensitivity Specificity PPV NPV
Any Steatosis (>2%) 4 3 %7 9 %7 0 %5 5 %
Steatosis >30% 6 0 %7 3 %3 0 %9 0 %
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association of genotype and BMI with steatosis in our
study is likely related to factors confounding the diagnosis
of steatosis on ultrasound, such as the additional presence
of fibrosis and inflammation.
Increased echogenicity is the characteristic ultrasono-
graphic finding that identifies hepatic steatosis. The
increased echogenicity is often compared to the spleen
and kidney [16,17]. A loss of definition of the hemi-dia-
phragm and decreased detail of the intrahepatic architec-
ture (particularly the portal veins) may be supportive
findings [11]. The performance characteristics of ultra-
sonography in the detection of steatosis vary considerably
among studies. In the examination of patients with
mostly alcoholic liver disease, a specificity of 84% and
sensitivity of 94% for the detection of steatosis on ultra-
sound was described [18]. Using multiple criteria to diag-
nose steatosis, positive predictive values can be as high as
94% in high-prevalence populations [19]. Performance
characteristics tend to improve with the diagnosis of mod-
erate and severe steatosis [11]. One study suggested that
33% steatosis seen on biopsy was an optimal threshold
for the radiographic detection of steatosis [20].
However, concomitant liver pathology may complicate
the diagnosis of steatosis on ultrasound. Echogenicity on
ultrasound may be consistent with either fibrosis or stea-
tosis, and ultrasonography may not effectively differenti-
ate between these two conditions [8]. Due to the overlap
in appearance of fibrosis and steatosis, some radiologists
opt to utilize the terms "fatty-fibrotic" [16,21] or "steatofi-
brosis" [22] when describing this echogenic pattern.
Fibrosis has been demonstrated to be independently asso-
ciated with steatosis in hepatitis C patients [6,14,23].
Some authors do not recommend the use of ultrasound as
a screening tool for hepatic steatosis due to questions
regarding sensitivity and specificity of this test [24].
Our results suggest that ultrasound is an unreliable predic-
tor of steatosis when described on a routine ultrasound
report in HCV-infected patients. These findings are con-
sistent with a prior study of hepatic steatosis which docu-
mented no correlation between biopsy and
ultrasonography in 64 patients with a positive HCV anti-
body [9]. Our results differed slightly from this previous
report in that some correlation between ultrasound and
biopsy was demonstrated (rs = 0.27). However, both false-
positives and false-negatives were observed in our study.
A report of steatosis was equally likely to indicate signifi-
cant steatosis or fibrosis. Therefore, we conclude that hep-
atitis C produces significant liver pathology that may
confound the diagnosis of steatosis on liver ultrasound in
a clinical setting. It may be advisable for radiologists to
report 'echogenic liver', 'possible steatosis vs. fibrosis' or
'bright liver', instead of definitively reporting the observa-
tion of steatosis.
For the clinician, ultrasound could conceivably be utilized
in the documentation of an echogenic liver only. Simi-
larly, any report of steatosis, fibrosis, or inflammation
could be understood by the clinician as consistent with
the presence of liver pathology. However, we also
observed false negatives in our study, in which patients
with significant steatosis had normal ultrasound reports.
Additionally, the prognostic significance for clinical
course and response to therapy may be very different for
steatosis compared to fibrosis, and therefore the signifi-
cance of an echogenic liver on ultrasound may vary sub-
stantially between patients.
Certain limitations of the study should be mentioned. The
patients in this study had been referred for specialty eval-
uation in a hepatitis C clinic in which therapeutic clinical
trials are emphasized. These patients may be different
than the general population with HCV infection, limiting
the generalizability of our results. Selection bias that is
inherent in retrospective studies may limit the applicabil-
ity of our results. Also, for some patients, there was time
between the dates in which the ultrasound and biopsy
were performed. It is possible that small changes in liver
histology could have occurred, if the patient had signifi-
cant weight gain or loss, for example. Ethanol consump-
tion was not measured in our study, which could have
impacted some of the baseline variables which were com-
pared between patients with or without steatosis on
ultrasound.
The retrospective nature of this study may introduce
potential bias in data collection which could limit the
clinical applicability of the findings. For example, some of
the ultrasounds were not performed within the same 1–2
weeks as the liver biopsy. In addition, incorporating the
radiologic interpretations of multiple radiologists (in con-
trast to a single radiologist) has certain advantages and
disadvantages. While multiple radiologists potentially
introduce significant variability in interpretation, they
more accurately simulate a realistic clinical scenario as
opposed to the artificial framework of a study utilizing a
single expert radiologist. Since our study focused on the
utility of ultrasonography results for clinicians, examining
this question in the context of multiple radiologists over
time seemed most appropriate. A similar review in other
clinical systems, such as medical systems from other coun-
tries, would be useful. It is possible that in other systems,
radiology do not attempt to define steatosis, but rather
only remark on the presence and degree of an echogenic
liver. It would also be interesting to survey radiologists to
attempt to assess the range of techniques and criteria for
the assessment of steatosis on ultrasonography.BMC Gastroenterology 2005, 5:14 http://www.biomedcentral.com/1471-230X/5/14
Page 7 of 8
(page number not for citation purposes)
Additionally, liver biopsy itself is not always a definitive
test, as sampling error can occur with this procedure. Dif-
ferences in the assessment of histologic stage and grade
have been observed in patients with hepatitis C who have
undergone simultaneous liver biopsies in different lobes
[25]. This error may account for some of the false-positive
ultrasound reports in the assessment of steatosis in our
study.
Conclusion
Unfortunately, routine hepatic ultrasonography does not
provide an accurate non-invasive mechanism for the diag-
nosis of hepatic steatosis in HCV-infected patients in the
clinical context of our study. These findings should be
examined in other clinical settings, perhaps in other coun-
tries. Clinicians should interpret a report of steatosis on
ultrasound with caution, and also consider that this report
could suggest a combination of inflammation, steatosis
and/or fibrosis. Even patients who did not have a liver
biopsy were included in the analysis of associations with
steatosis, and the description of steatosis on ultrasound
was associated with factors reflective of hepatic inflamma-
tion (such as ALT). Conversely, lack of ultrasonographic
evidence of steatosis does not definitively exclude the
presence of steatosis as shown on biopsy. Until a non-
invasive modality is proven to be superior in a clinical set-
ting, liver biopsy remains the optimal diagnostic proce-
dure for the determination of steatosis in patients infected
with hepatitis C.
List of abbreviations
AFP Alpha-fetoprotein
ALT Alanine aminotransferase
BMI Body mass index
CI Confidence interval
HCV Hepatitis C virus
OR Odds ratio
PCR Polymerase chain reaction
RNA Ribonucleic acid
US Ultrasonography
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
MH and EL developed the initial concept of the study. All
authors participated in study design and data analysis. JV
and EF conducted the histologic review of the slides. MH
conducted the review of ultrasound reports and organiza-
tion of the data. All authors contributed to the manuscript
preparation and completion.
Acknowledgements
The opinions or assertions contained herein are those of the authors and 
are not to be construed as official policy or as reflecting the views of the 
Department of the Army or the Department of Defense. The authors are 
employees of the U.S. Government. This work was prepared as part of 
their official duties and, as such, there is no copyright to be transferred. 
This study was presented in part as a podium presentation at Digestive Dis-
eases Week, Orlando FL, May 19–22, 2003.
References
1. Ramalho F: Hepatitis C virus infection and liver steatosis. Anti-
viral Res 2003, 60:125-7.
2. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y,
Miyamura T, Koike K.: Hepatitis C core protein induces hepatic
steatosis in transgenic mice. J Gen Virol 1997, 78:1527-1531.
3. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y,
Koike K, Pessayre D, Chapman J, Barba G, Brechot C: Hepatitis C
virus core protein inhibits microsomal triglyceride transfer
protein activity and very low density lipoprotein secretion: a
model of viral-related steatosis. FASEB J 2002, 16:185-194.
4. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM: Hepatitis C
virus NS5A colocalizes with the core protein on lipid drop-
lets and interacts with apolipoproteins.  Virology 2002,
292:198-210.
5. Kumar D, Farrell GC, Fung C, George J: Hepatitis C virus geno-
type 3 is cytopathic to hepatocytes: reversal of hepatic stea-
tosis after sustained therapeutic response. Hepatology 2002,
36:1266-1272.
6. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL: Steatosis in
chronic hepatitis C: relative contributions of obesity, diabe-
tes mellitus, and alcohol. Hepatology 2002, 36:729-736.
7. Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, Doske-
land B, Maeland A, Lund-Tonnesen S, Myrvang B: Effect of com-
bined interferon-α  induction therapy and ribavirin on
chronic hepatitis C virus infection: a randomized multicen-
tre study. Scand J Gastroenterol 2002, 37:226-232.
8. Fontana RJ, Lok AS: Noninvasive monitoring of patients with
chronic hepatitis C. Hepatology 2002, 36:S57-S64.
9. Kutcher R, Smith GS, Sen F, Gelman SF, Mitsudo S, Thung SN, Reinus
JF: Comparison of sonograms and liver histologic findings in
patients with chronic hepatitis C virus infection. J Ultrasound
Med 1998, 17:321-325.
10. The French METAVIR Cooperative Study Group: Intraobserver
and interobserver variations in liver biopsy interpretation in
patients with chronic hepatitis C. Hepatology 1994, 20:15-20.
11. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD: Com-
parison of liver histology with ultrasonography in assessing
diffuse parenchymal liver disease. Clin Radiol 1991, 43:26-31.
12. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M,
Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological
imaging in nonalcoholic fatty liver disease.  Gastroenterology
2002, 123:745-50.
13. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Host- and disease-
specific factors affecting steatosis in chronic hepatitis C. J
Hepatol 1998, 29:198-206.
14. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C,
Clouston A, Powell EE: Fibrosis in chronic hepatitis C corre-
lates significantly with body mass index and steatosis. Hepa-
tology 1999, 29:1215-1219.
15. Bayati N, Silverman AL, Gordon SC: Serum alpha-fetoprotein
levels and liver histology in patients with chronic hepatitis C.
Am J Gastroenterol 1998, 93:2452-2456.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Gastroenterology 2005, 5:14 http://www.biomedcentral.com/1471-230X/5/14
Page 8 of 8
(page number not for citation purposes)
16. Joy D, Thava VR, Scott BB: Diagnosis of fatty liver disease: is
biopsy necessary? Eur J Gastroenterol Hepatol 2003, 15:539-543.
17. Kurtz AB, Middleton WD: Ultrasound. The Requisites New York:
Mosby; 1996:16-18. 
18. Saverymuttu SH, Joseph AE, Maxwell JD: Ultrasound scanning in
the detection of hepatic fibrosis and steatosis. Brit Med J 1986,
292:13-15.
19. Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U,
Fryden A, Bodemar G: Increased liver echogenicity at ultra-
sound examination reflects degree of steatosis but not fibro-
sis in asymptomatic patients with mild-moderate
abnormalities of liver transaminases.  Digest Liver Dis 2002,
34:516-522.
20. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M,
Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological
imaging in nonalcoholic fatty liver disease.  Gastroenterology
2002, 123:745-750.
21. Needleman L, Kurtz AB, Rifkin MD, Cooper HS, Pasto ME, Goldberg
BB: Sonography of diffuse benign liver disease: accuracy of
pattern recognition and grading.  Am J Roentgenol 1986,
146:1011-1015.
22. Debongnie JC, Pauls C, Fievez M, Wibin E: Prospective evaluation
of the diagnostic accuracy of liver ultrasonography. Gut 1981,
22:130-135.
23. Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Paw-
lotsky JM, Dhumeaux D: Worsening of steatosis is an independ-
ent factor of fibrosis progression in untreated patients with
chronic hepatitis C and paired liver biopsies.  Gut 2003,
52:288-292.
24. Siegelman ES, Rosen MA: Imaging of hepatic steatosis. Semin Liver
Dis 2001, 21:71-80.
25. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos
NT, Feng ZZ, Reddy KR, Schiff ER: Sampling error and intraob-
server variation in liver biopsy in patients with chronic HCV
infection. Am J Gastroenterol 2002, 97:2614-2618.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/5/14/pre
pub